We serve 2-Morpholinophenol CAS:41536-44-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Morpholinophenol
CAS.NO:41536-44-1
Molecular Formula: ：C10H13NO2
Molecular Weight: 179.21600
Synonyms:
2-morpholin-4-ylphenol
Physical and Chemical Properties:
Boiling point: 130ºC (0.1 torr)
Melting point: 126ºC
Flash point: 144.652ºC
Refractive index: 1.575
Specification:
Appearance:White powder
Purity:≥98.0%
Moisture Content: 0.25%
Impurity: 0.3%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:An important raw material and intermediate used in Organic Synthesis,Pharmaceuticals.
Contact us for information like 2-Morpholinophenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-morpholin-4-ylphenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-morpholin-4-ylphenol Use and application,2-morpholin-4-ylphenol technical grade,usp/ep/jp grade.
Related News: A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.2-Bromo-5-chlorobenzotrifluoride manufacturer A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.BROMOIODOMETHANE supplier The Philippines, the United States and Australia have expanded travel restrictions, temporarily barring noncitizens who have recently traveled to China.(2S,5R)-5-(benzyloxyamino)-piperidine-2-carboxylic acid amide vendor In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.
